Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Capital Leases (2016 - 2020)

Outlook Therapeutics (OTLK) has disclosed Capital Leases for 6 consecutive years, with $49162.0 as the latest value for Q2 2020.

  • On a quarterly basis, Capital Leases fell 98.53% to $49162.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $49162.0, a 98.53% decrease, with the full-year FY2019 number at $3.4 million, down 2.53% from a year prior.
  • Capital Leases was $49162.0 for Q2 2020 at Outlook Therapeutics, down from $3.3 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $3.5 million in Q1 2018 to a low of $28067.0 in Q3 2017.
  • A 5-year average of $1.8 million and a median of $2.1 million in 2016 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: surged 12203.62% in 2018, then tumbled 98.53% in 2020.
  • Outlook Therapeutics' Capital Leases stood at $113082.0 in 2016, then tumbled by 62.43% to $42481.0 in 2017, then soared by 7903.87% to $3.4 million in 2018, then dropped by 1.64% to $3.3 million in 2019, then tumbled by 98.53% to $49162.0 in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Capital Leases are $49162.0 (Q2 2020), $3.3 million (Q1 2020), and $3.3 million (Q4 2019).